This presentation demonstrates how AI-integrated platforms are transforming therapeutic development through three commercial solutions at Bioelectronica:

- Hypercell Platform® combines computer vision with AI-powered single-cell analysis for next-generation antibody discovery through intelligent cell sorting and real-time analytics. Over 90+ discovery campaigns have demonstrated significant reduction in lead identification timelines while improving candidate quality through AI-guided selection.

- AbFinder Software™ leverages machine learning for antibody sequence optimization and developability prediction in drug discovery pipelines. This cloud-based platform enables data-driven therapeutic antibody hit selection, reducing late-stage failures through predictive analytics and automated candidate ranking for pharmaceutical applications.

- SmartCulture X™ applies AI-optimized imaging & automation to microbiome screening for live biotherapeutics development. The platform supports next-generation microbiome-based treatments through intelligent strain isolation and characterization workflows.

These integrated platforms showcase quantifiable improvements in drug discovery efficiency, from months to weeks in lead identification, while enabling previously impossible therapeutic modalities through AI-enhanced detection capabilities.